Comparative Study of Oral and Vaginal Misoprostol for Induction of Labour, Maternal and Foetal Outcome
Background: Misoprostol is a new promising agent for cervical ripening and induction of labour .The ideal dose, route and frequency of administration of misoprostol are still under investigation. Although, vaginal application of misoprostol has been validated as a reasonable mean of induction, t...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
JCDR Research and Publications Private Limited
2013-12-01
|
Series: | Journal of Clinical and Diagnostic Research |
Subjects: | |
Online Access: | https://jcdr.net/articles/PDF/3779/58-%205825_E(C)_F(T)_PF1(MH)_PFA(H)_OLF.pdf |
Summary: | Background: Misoprostol is a new promising agent for cervical
ripening and induction of labour .The ideal dose, route and
frequency of administration of misoprostol are still under
investigation. Although, vaginal application of misoprostol has
been validated as a reasonable mean of induction, there is a
patient resistance to digital examination and there is a risk of
ascending infection. For this reason, oral administration of
misoprostol for cervical ripening and labour induction has been
tried.
Aims and Objectives: To compare 50µg of oral misoprostol
versus 25µg of intravaginal misoprostol for induction of labour at
term and maternal, foetal outcomes.
Methods: Two hundred women who were at term, with indication
for induction of labour and Bishop scores of ≤5 were randomly
assigned to receive misoprostol 50µg or 25µg intravaginal, every
4-6 hours, for a maximum of 5 doses. In either group, pregnant
females with inadequate uterine contractions despite being
given maximum 5 doses of misoprostol, were augmented using
oxytocin. The primary outcome measure was time-interval from
induction to vaginal delivery and vaginal delivery rate within 24
hours.
Results: The median induction to vaginal delivery time in oral
group (12.92h) and vaginal group (14.04 h) was not significant.
Oral misoprostol resulted in more number of vaginal deliveries
as compared to vaginal misoprostol (94% as compared to
86%), which was not significant. There was a significantly
higher incidence of uterine tachysystole in the vaginal group, as
compared to oral group. There were no significant differences
between the groups with respect to oxytocin augmentation,
caesarean section rate, analgesic requirement and neonatal
outcome.
Conclusion: Oral misoprostol is as efficacious as vaginal
misoprostol because of shorter induction delivery interval, lower
caesarean section rates, and lower incidence of failed induction
rates. Lower incidence of foetal distress and easy intake are
observed if the drug is administered orally. |
---|---|
ISSN: | 2249-782X 0973-709X |